| 04/18/2025 15:30 |
The Yield Results of the Third Commercial Production Run for AKUUGO(R) Suspension for Intracranial Implantation |
| 03/18/2025 15:30 |
Presentation for Financial Results for the Fiscal Year Ending January 31, 2025 |
| 03/17/2025 15:30 |
Notice Concerning Differences between Consolidated Earnings Forecast and Actual Results for the Fiscal Year Ending January 31, 2025 |
| 03/17/2025 15:30 |
Notice Concerning Recording of Non-operating Income, Non-operating Expenses, Extraordinary Gains, and Deferred Income Taxes |
| 03/17/2025 15:30 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
| 03/17/2025 15:30 |
Consolidated Financial Results for the Fiscal Year Ended January 31, 2025[Japanese GAAP] |
| 02/12/2025 11:00 |
Publication of Results of Cell Implantation Location Analysis from STEMTRA Trial in Neurotrauma Reports |
| 02/06/2025 15:30 |
The Results of the Second Commercial Production Run of AKUUGO(R) |
| 02/05/2025 15:30 |
[Delayed] Conclusion of Contract Manufacturing Agreement with JCR Pharma for Trial Production of AKUUGO |
| 02/04/2025 16:30 |
Determination of Terms and Conditions of Stock Options(Share Acquisition Rights) |
| 02/04/2025 16:30 |
Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2025 |
| 01/20/2025 16:35 |
Announcement on Granting Stock Options (Share Acquisition Rights) |
| 01/07/2025 15:30 |
Publication of an Article in Molecular Therapy of SB623 |
| 12/16/2024 15:30 |
Announcement on Acquisition and Cancellation of Stock Options (Share Acquisition Rights) |
| 12/16/2024 15:30 |
Notice Concerning Recording of Non-operating Income, Extraordinary Gains, and Deferred Income Taxes |
| 12/16/2024 15:30 |
Consolidated Financial Results for the Nine Months Ended October 31, 2024 [Japanese GAAP] |
| 12/06/2024 15:30 |
The Yield Results of the Second Commercial Production Run for AKUUGO(R) |
| 10/30/2024 15:00 |
Notice Concerning the Grant of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the United States |
| 09/18/2024 15:00 |
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2025 |
| 09/17/2024 15:00 |
Notice Concerning Recording of Non-operating Income and Deferred Income Taxes |
| 09/05/2024 16:30 |
Positive Results of SB623 for Chronic Effects of TBI, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology |
| 07/29/2024 15:00 |
[Delayed] Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US |
| 07/10/2024 10:30 |
[Delayed] [Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of SB623 |
| 06/20/2024 09:30 |
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan |
| 06/13/2024 15:00 |
Consolidated Financial Results for the Three Months Ended April 30, 2024 [Japanese GAAP] |
| 06/13/2024 15:00 |
Notice Concerning Recording of Non-operating Income and Deferred Income Taxes |
| 06/12/2024 15:00 |
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan |
